Financial Tear Sheet

Corporate Profile

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Our most advanced program is QINPREZO™ (vosaroxin), our product candidate for the potential treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. Sunesis has built a highly experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer.

Vosaroxin is currently being evaluated in patients with relapsed or refractory AML, frontline AML and myelodysplastic syndrome (MDS) and MDS in patients who have failed frontline treatment with hypomethylating agents. In October 2014, the company announced results from its Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal VALOR (**V**osaroxin and **A**ra-C combination eva**L**uating **O**verall survival in **R**elapsed/refractory AML) trial. VALOR was designed to evaluate the effect of vosaroxin in combination with cytarabine on overall survival as compared to placebo in combination with cytarabine. The trial was conducted at 124 study sites in 15 countries. Patients treated with vosaroxin achieved increased overall survival compared to those treated with placebo (7.5 months vs 6.1 months, HR=0.87), the primary endpoint, but this difference did not achieve statistical significance (p=0.06). The complete remission (CR) rate, the sole secondary efficacy endpoint in the trial, did demonstrate a significant difference for the vosaroxin combination arm (30.1% vs 16.3%, $p < 0.0001$). Detailed results of the VALOR trial were presented in the "Late Breaking Abstracts" session of the American Society of Hematology (ASH) Annual Meeting in December 2014.

In November 2014, based on results of the trial, we submitted a letter of intent to the European Medicines Agency (EMA) describing our intention to file a marketing authorization application (MAA) for marketing authorization of vosaroxin plus cytarabine for the treatment of relapsed or refractory AML. In June 2015, we met separately with our Rapporteur and Co-Rapporteur who are two appointed members of the EMA's Committee of Human Medicinal Products. Based upon feedback from these meetings, we plan to file an MAA with the EMA as soon as practicable. In July 2015, we met with the U.S. Food and Drug Administration (FDA) to discuss a potential regulatory filing in the United States. Based upon the meeting, the FDA recommended that we provide additional clinical evidence prior to any regulatory filing in the U.S. As a result, we will evaluate regulatory and clinical strategies with the goal of gaining future marketing approval in the U.S.

We own worldwide development and commercialization rights to vosaroxin. In 2009, vosaroxin received orphan drug designation for the potential treatment of AML from the FDA and in 2012, the European Commission granted orphan drug designation to vosaroxin for the treatment of AML, which may provide for 10 years of marketing exclusivity in all member countries of the European Union following product approval for this indication in Europe. In 2011, the FDA granted fast track designation to vosaroxin for the

potential treatment of relapsed or refractory AML in combination with cytarabine.

In January 2014, we announced the expansion of our oncology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec MA, Inc., is for global commercial rights to SNS-062, a selective non-covalently binding oral inhibitor of Bruton's tyrosine kinase (BTK).

The second agreement, with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, is for global commercial rights to several potential first-in-class, pre-clinical inhibitors of the novel target phosphoinositide-dependent kinase-1 (PDK1).

Stock Quote

SNSS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	$3.09
Change (%)	▲ 0.02 (0.65%)
Volume	30,878
52 Week Low	$2.76
Market Cap	$66,313,078
Rolling EPS	-2.19
PE Ratio	N/A
Shares Outstanding	21,460,543

Data as of 05/26/17 4:00 p.m. ET

Stock Chart

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
05/08/17	Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
05/01/17	Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
04/03/17	Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored

Upcoming Events

There are currently no events scheduled.

Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting

Analyst Ratings

1-Strong Buy	1
2-Buy	0
3-Hold	2
4-Underperform	0
5-Sell	0

Mean Recommendation: 2.3



SEC Filings

Filing Date	Form
05/22/17	CT ORDER
05/10/17	S-8
05/08/17	10-Q
05/08/17	8-K

Investor and Media Inquiries:

Maeve Conneighton
Argot Partners
206.899.4940

Dan Swisher
Sunesis Pharmaceuticals, Inc.
650-266-3715

Board of Directors

Steve R. Carchedi	Director
Matthew K. Fust	Director
Steven B. Ketchum, Ph.D.	Director
Dayton Misfeldt	Director
Geoffrey M. Parker	Director
Homer L. Pearce, Ph.D.	Director
David C. Stump, M.D.	Director
Daniel N. Swisher, Jr.	Chief Executive Officer and President
James W. Young, Ph.D.	Chairman

Management

Daniel N. Swisher, Jr.	Chief Executive Officer and President
Judith A. Fox, Ph.D.	Chief Scientific Officer
Parvinder S. Hyare	Vice President, Global Oncology Operations
Gene Jamieson	Vice President, Technical Operations
Linda Neuman, MD, MBA	Vice President, Clinical Development
Jennifer A. Smith, Ph.D.	Vice President, Biometrics
Deborah A. Thomas, Ph.D.	Senior Vice President, Regulatory Affairs, Quality Assurance, and Nonclinical Development

Jennifer A. Troia	Vice President, Human Resources